Takuva, Simbarashe G.Takalani, AzwidhwiSeocharan, shenYende-Zuma, NonhlanhlaReddy, TaryleeEngelbrecht, ImkeFaesen, MarkKhuto, KentseWhyte, Carmen J.Bailey, VeroniqueTrivella, ValentinaPeter, JonathanOpie, JessicaLouw, VernonRowji, PradeepJacobson, BarryGroenewald, PamelaDorrington, Rob E.Laubscher, RiaBradshaw, DebbieMoultrie, HarryFairall, LaraSanne, IanGailBekker, LindaGray, GlendaGoga, Ameena EbrahimGarrett, Nigel2022-11-022022-11-022022-06-21Takuva, S., Takalani, A., Seocharan, I., Yende-Zuma, N., Reddy, T., Engelbrecht, I. et al. (2022) Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. PLoS Medicine 19(6): e1004024. https://doi.org/10.1371/journal.pmed.1004024.1549-1676 (online)1549-1277 (print)10.1371/journal.pmed.1004024https://repository.up.ac.za/handle/2263/88106Real-world evaluation of the safety profile of vaccines after licensure is crucial to accurately characterise safety beyond clinical trials, support continued use, and thereby improve public confidence. The Sisonke study aimed to assess the safety and effectiveness of the Janssen Ad26.COV2.S vaccine among healthcare workers (HCWs) in South Africa. Here, we present the safety data.en© 2022 Takuva et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.SafetyEffectivenessVaccinesJanssen Ad26.COV2.S vaccineHealthcare workers (HCW)South Africa (SA)Article